Impact of the Implementation of a Vancomycin Protocol on Trough Serum Vancomycin Concentrations in a Pediatric Intensive Care Unit
| Autor: | Cícero Armídio Gomes Dias, Raíssa Queiroz Rezende, Cláudia Pires Ricachinevsky, João Paulo de Lucena Capelari |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Heart disease Adolescent Non-Randomized Controlled Trials as Topic medicine.drug_class Antibiotics medicine.disease_cause Intensive Care Units Pediatric 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Vancomycin 030225 pediatrics Internal medicine Intensive care Medicine Humans Pharmacology (medical) Child Retrospective Studies Pediatric intensive care unit business.industry medicine.disease Confidence interval Staphylococcus aureus Child Preschool Pediatrics Perinatology and Child Health Female business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Paediatric drugs. 23(3) |
| ISSN: | 1179-2019 |
| Popis: | Vancomycin is an antibiotic that is widely used in pediatric intensive care, but the safe and effective use of this drug is challenging. This study aimed to assess the impact of a vancomycin protocol on trough serum concentrations. We conducted a retrospective quasiexperimental study in patients aged ≤ 18 years in intensive care who received vancomycin for at least 5 days. Patients were divided into two groups: before and after a protocol implemented in 2017 that suggested an initial vancomycin dose of 60 mg/kg/day, target serum levels of 15–20 μg/mL, and dose adjustments. We compared patient characteristics, target serum level achievement, and vancomycin levels over time. Each group contained 65 patients; most were male infants with heart disease as the main reason for hospitalization. Only 29.2% of the patients had pretreatment cultures for bacteria identification recorded, with 1.5% identified as methicillin-resistant Staphylococcus aureus. For the first serum levels, 10.8% of patients in the pre-protocol group and 21.5% in the post-protocol group achieved the 15–20 μg/mL target (p = 0.153); during the first 5 days of treatment, this proportion significantly increased from 52.3 to 73.8% (p = 0.018). We observed a difference between the first and fifth levels: 8.9 μg/mL (95% confidence interval [CI] − 3.1 to 21) pre-protocol and 0.4 μg/mL (95% CI − 6.1 to 6.9) post-protocol (p = 0.175). Reaching adequate trough vancomycin concentrations in critically ill pediatric patients remains a challenge, and clinical practice protocols allow better dose adjustment and control even when monitoring technologies are unavailable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink